Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.
作者信息
Salmanton-García Jon, Marchesi Francesco, Glenthøj Andreas, Bilgin Yavuz M, van Praet Jens, Dávila-Valls Julio, Martín-Pérez Sonia, Labrador Jorge, van Doesum Jaap, Falces-Romero Iker, Farina Francesca, Schönlein Martin, Chanut Mathilde, Petzer Verena, Espigado Ildefonso, Dargenio Michelina, Aujayeb Avinash, Sili Uluhan, Serrano Laura, Pinczés László Imre, de Jonge Nick, Soto-Silva Andrés, Buquicchio Caterina, Prezioso Lucia, Marchetti Monia, Meers Stef, Busca Alessandro, Corradini Paolo, Hoenigl Martin, Koehler Philipp, Rahimli Laman, Çolak Gökçe Melis, Arellano Elena, Wolf Dominik, Gräfe Stefanie, Ammatuna Emanuele, Berg Venemyr Caroline, Cornely Oliver A, Pagano Livio
机构信息
University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Germany.
University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Germany.
出版信息
Hemasphere. 2022 Oct 25;6(11):e789. doi: 10.1097/HS9.0000000000000789. eCollection 2022 Nov.
Abstract
摘要
相似文献
1
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.
Hemasphere. 2022 Oct 25;6(11):e789. doi: 10.1097/HS9.0000000000000789. eCollection 2022 Nov.
2
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.
Am J Hematol. 2022 Aug;97(8):E312-E317. doi: 10.1002/ajh.26626. Epub 2022 Jun 28.
3
COVID-19 in patients with hematologic malignancy.
Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251.
4
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report.
J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):225-227. doi: 10.18176/jiaci.0845. Epub 2022 Jul 27.
5
Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases.
Asian Pac J Cancer Prev. 2022 Jun 1;23(6):2049-2055. doi: 10.31557/APJCP.2022.23.6.2049.
6
Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.
Front Immunol. 2022 Jul 28;13:934476. doi: 10.3389/fimmu.2022.934476. eCollection 2022.
7
Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
JAMA Netw Open. 2021 Sep 1;4(9):e2123622. doi: 10.1001/jamanetworkopen.2021.23622.
8
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
9
Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel.
JAMA Netw Open. 2022 Aug 1;5(8):e2224657. doi: 10.1001/jamanetworkopen.2022.24657.
10
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
JAMA Oncol. 2022 May 1;8(5):748-754. doi: 10.1001/jamaoncol.2022.0001.
引用本文的文献
1
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.
Am J Hematol. 2025 Mar;100(3):358-374. doi: 10.1002/ajh.27565. Epub 2024 Dec 23.
2
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.
Adv Ther. 2025 Feb;42(2):666-719. doi: 10.1007/s12325-024-03043-0. Epub 2024 Dec 16.
3
[Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):923-930. doi: 10.3760/cma.j.cn121090-20240621-00230.
4
Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG).
Ann Hematol. 2024 Dec;103(12):5713-5727. doi: 10.1007/s00277-024-05744-6. Epub 2024 Apr 22.
5
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.
EClinicalMedicine. 2024 Mar 18;71:102553. doi: 10.1016/j.eclinm.2024.102553. eCollection 2024 May.
6
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Infection. 2024 Jun;52(3):1125-1141. doi: 10.1007/s15010-023-02169-7. Epub 2024 Feb 22.
7
Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.
Open Forum Infect Dis. 2023 Nov 2;10(11):ofad550. doi: 10.1093/ofid/ofad550. eCollection 2023 Nov.
8
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases.
Ann Hematol. 2024 Jan;103(1):351-355. doi: 10.1007/s00277-023-05484-z. Epub 2023 Oct 2.
9
Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease.
Blood Cancer J. 2023 Sep 5;13(1):133. doi: 10.1038/s41408-023-00897-5.
10
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
J Infect Dis. 2023 Aug 4;228(Suppl 1):S55-S69. doi: 10.1093/infdis/jiad174.
本文引用的文献
1
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.
Am J Hematol. 2022 Aug;97(8):E312-E317. doi: 10.1002/ajh.26626. Epub 2022 Jun 28.
2
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.
Blood Cancer J. 2022 May 31;12(5):86. doi: 10.1038/s41408-022-00684-8.
3
COVID-19 in patients with hematologic malignancy.
Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251.
4
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).
Leukemia. 2022 Jun;36(6):1467-1480. doi: 10.1038/s41375-022-01578-1. Epub 2022 Apr 29.
5
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
Nat Med. 2022 Jul;28(7):1486-1490. doi: 10.1038/s41591-022-01832-0. Epub 2022 Apr 25.
6
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
N Engl J Med. 2022 May 5;386(18):1712-1720. doi: 10.1056/NEJMoa2201570. Epub 2022 Apr 5.
7
Is COVID vaccine effective in patients with myeloid malignancy?
Br J Haematol. 2022 Jun;197(6):656-658. doi: 10.1111/bjh.18155. Epub 2022 Apr 5.
8
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas.
Am J Pathol. 2022 Apr;192(4):642-652. doi: 10.1016/j.ajpath.2022.01.007. Epub 2022 Feb 3.
9
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
10
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
Zotero 插件